---
title: "Why No. 2 IBD 50 stock, Liquidia, dropped despite its sales beat"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295705531.md"
description: "Liquidia topped Wall Street's second-quarter expectations Wednesday as sales of its lung disease treatment, Yutrepia, grew by double digits."
datetime: "2026-08-12T20:24:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295705531.md)
  - [en](https://longbridge.com/en/news/295705531.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295705531.md)
generator: "portal-rs"
---

# Why No. 2 IBD 50 stock, Liquidia, dropped despite its sales beat

Liquidia topped Wall Street's second-quarter expectations Wednesday as sales of its lung disease treatment, Yutrepia, grew by double digits.

### Related Stocks

- [LQDA.US](https://longbridge.com/en/quote/LQDA.US.md)

## Related News & Research

- [Engineers Gate Manager LP Sells 17,412 Shares of Liquidia Corporation $LQDA](https://longbridge.com/en/news/298887857.md)
- [Liquidia Director Sold Shares Worth Over $1.1M](https://longbridge.com/en/news/299094246.md)
- [Viking Therapeutics Advances VK2735 Obesity Drug Into Phase 3 After 15% Weight Loss](https://longbridge.com/en/news/298988404.md)
- [Weight Loss Trial Results Altering The Investment Case For Structure Therapeutics (GPCR)?](https://longbridge.com/en/news/298754574.md)
- [Definium's LSD-based drug lowers anxiety in new late-stage trial, shares soar](https://longbridge.com/en/news/298913820.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**